International Psoriasis Council

Advancing Knowledge. Improving Care.

Announcing IPC’s New Leadership for 2025

The International Psoriasis Council is governed by a volunteer Board of Directors comprised of the world’s leading experts in psoriasis who provide business expertise to the organization. We are excited to announce the newest IPC leadership changes within the IPC Board of Directors, effective January 1, 2025.

Bruce Strober, MD, PhD, from the United States, will begin his term as President, which will last from 2025 to 2026. Claudia de la Cruz, MD, from Chile, has been elected as Vice President/President-Elect; Catherine Smith, MD, from the United Kingdom, has been elected as Secretary; and Joel Gelfand, MD, PhD, from the United States, will continue to serve as Treasurer. Hervé Bachelez, MD, PhD, from France, will also serve as the Immediate Past President for one more year.

The IPC Board of Directors plays a crucial role in guiding the direction and strategy of our organization as we work to improve psoriasis patient care worldwide.

Please join us in congratulating our newly elected officers and acknowledging their ongoing dedication to the IPC!

Meet Our New Board Officers

Bruce Strober, MD, PhD

Yale University and Central Connecticut Dermatology

Cromwell, Connecticut, United States

IPC President

Bio

Claudia de la Cruz, MD

Clinica Dermacross

Santiago, Chile

IPC Vice President/President-Elect

Bio

Joel Gelfand, MD, MSCE

University of Pennsylvania

Philadelphia, Pennsylvania, United States

IPC Treasurer

Bio

Catherine Smith, MD

Kings College London, and Guys and St Thomas NHS Foundation Trust

London, United Kingdom

IPC Secretary

Bio

Hervé Bachelez, MD, PhD

Hôpital Saint-Louis, Imagine Institute for Human Genetic Diseases, Paris Cité University

Paris, France

IPC Councilor

Bio

A complete list of our Board of Directors with their full biographies can be found here.

Categories

Recent Posts

Approaching Challenging Patient Interactions with Empathy

Next Generation of Leaders: 2025 IPC Fellows Transition to Jr. Councilors

Highlights from the 2026 American Academy of Dermatology (AAD) Annual Meeting: Diagnostic Complexity, Therapeutic Advances, and Emerging Research

Also Read

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.

What's New

First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study

In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.

Read More »

Recent Advances in Psoriasis: A Year in Review

In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.

WATCH NOW

Monday, April 6, 2026